Medicenna Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Medicenna Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 1.4% bzw. 62.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 0.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14% betragen.

Wichtige Informationen

1.4%

Wachstumsrate der Gewinne

0.23%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	62.8%
Zukünftige Eigenkapitalrendite	13.96%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Sep 30

Medicenna extends period to exercise certain warrants

Medicenna Therapeutics (NASDAQ:MDNA) received conditional approval from the TSX to extend the expiry date of the common share purchase warrants of the company originally issued on October 17, 2019. The warrants, of which 1,549,052 are available to be extended, are exercisable for common shares of the company at a price of $1.75/common share and are set to expire on October 17, 2022, will now expire on July 17, 2023, an extension of 9 months. All other terms of the warrants, including the exercise price, remain unchanged. There are 1,661,552 warrants remaining available for exercise including 112,500 warrants held directly or indirectly by insiders of the company which will not be extended.

Seeking Alpha • Sep 13

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Medicenna Therapeutics (NASDAQ:MDNA) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its agonist in combination with cancer drug Keytruda in its ongoing phase 1/2 study named ABILITY. Medicenna's (MDNA) agonist, MDNA11, is being assessed in the early- to mid-stage trial as a monotherapy and in combination with MRK's Keytruda to treat patients with cancerous tumors. As per the clinical trial collaboration deal, MDNA will sponsor the study and MRK will supply Keytruda. "Although we believe that MDNA11 has great potential as a single agent, combining it with Keytruda may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11," MDNA CEO Fahar Merchant said in a statement. MDNA stock +1.5% to $1.03 in afternoon trading.

Seeking Alpha • Aug 15

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics press release (NASDAQ:MDNA): Q1 GAAP EPS of -$0.07 in-line. Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022.

Seeking Alpha • Aug 08

Medicenna Therapeutics stock slides on launch of units offering

Medicenna Therapeutics (NASDAQ:MDNA) shares fell 6% in Monday's extended session after the immunotherapy company announced the launch of an underwritten public offering of units in the U.S. Each unit will be comprised of one common share and one warrant to purchase common shares. The offering is expected to be priced in the context of the market, with the final terms to be determined at the time of pricing. The company plans to use the net proceeds primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

Gewinn- und Umsatzwachstumsprognosen

OTCPK:MDNA.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2029	37	-26	-86	19	3
3/31/2028	7	-44	-99	-22	3
3/31/2027	1	-34	-57	87	3
3/31/2026	N/A	-20	-28	-19	2
12/31/2025	N/A	-13	-18	-18	N/A
9/30/2025	N/A	-14	-17	-17	N/A
6/30/2025	N/A	-13	-18	-18	N/A
3/31/2025	N/A	-12	-17	-16	N/A
12/31/2024	N/A	-27	-16	-16	N/A
9/30/2024	N/A	-27	-17	-17	N/A
6/30/2024	N/A	-26	-15	-15	N/A
3/31/2024	N/A	-25	-16	-16	N/A
12/31/2023	N/A	-15	-14	-14	N/A
9/30/2023	N/A	-12	-13	-13	N/A
6/30/2023	N/A	-9	-14	-14	N/A
3/31/2023	N/A	-10	-13	-13	N/A
12/31/2022	N/A	-9	-13	-13	N/A
9/30/2022	N/A	-13	-16	-16	N/A
6/30/2022	N/A	-20	-21	-21	N/A
3/31/2022	N/A	-23	-24	-24	N/A
12/31/2021	N/A	-25	-23	-23	N/A
9/30/2021	N/A	-26	-20	-20	N/A
6/30/2021	N/A	-21	-17	-17	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-14	-16	-16	N/A
9/30/2020	N/A	-11	-14	-14	N/A
6/30/2020	N/A	-9	-5	-5	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-7	-5	-5	N/A
9/30/2019	N/A	-6	N/A	-5	N/A
6/30/2019	N/A	-5	N/A	-8	N/A
3/31/2019	N/A	-5	N/A	-8	N/A
12/31/2018	N/A	-5	N/A	-9	N/A
9/30/2018	N/A	-5	N/A	-10	N/A
6/30/2018	N/A	-6	N/A	-11	N/A
3/31/2018	N/A	-7	N/A	-10	N/A
12/31/2017	N/A	-11	N/A	-10	N/A
9/30/2017	N/A	-11	N/A	-8	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-8	N/A	-7	N/A
12/31/2016	N/A	-3	N/A	-6	N/A
9/30/2016	N/A	-2	N/A	-5	N/A
6/30/2016	N/A	-1	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDNA.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MDNA.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MDNA.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MDNA.FDie Einnahmen des Unternehmens (62.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.8% pro Jahr).

Hohe Wachstumseinnahmen: MDNA.FDie Einnahmen des Unternehmens (62.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MDNA.FDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/26 20:36
Aktienkurs zum Tagesende	2026/05/26 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Medicenna Therapeutics Corp. wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Charles Zhu	Guggenheim Securities, LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.
Dev Prasad	Lucid Capital Markets

Medicenna Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.9% to US$5.83

Price target decreased to US$7.00

No longer forecast to breakeven

Price target decreased to US$8.40

Price target increased to US$10.50

Forecast to breakeven in 2025

Recent updates

Medicenna Therapeutics Corp. has filed a Follow-on Equity Offering.

Medicenna Therapeutics Corp Announces First Patient Dosed in Neo-Cyt Study of Mdna11 in Neoadjuvant Melanoma

Medicenna Therapeutics Corp Announces Presentation Of NEOCYT Trial At ASCO

Medicenna Therapeutics Corp Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of Its First-In-Class Anti-Pd-1 X Il-2 Bifunctional Superkine Mdna113 At Aacr

Medicenna Therapeutics Corp. Appoints Nageatte Ibrahim as Chief Medical Officer

Medicenna Therapeutics Corp Presents Preclinical Data for Mdna113 Bifunctional Superkine

Medicenna Therapeutics Corp. Announces Board Changes, Effective February 12, 2026

Medicenna Therapeutics Corp. Announces Key Program Updates and 2026 Outlook

Medicenna Therapeutics Corp. Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Medicenna Therapeutics Corp. Announces John H. Sampson Not Standing for Re-Election

Medicenna Therapeutics Corp., Annual General Meeting, Sep 25, 2025

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

Medicenna Therapeutics Corp. Reports Mdna11's Compelling Anti-Cancer Activity Is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells At the Inaugural Aacr-Oncology Conference and Provides Ability-Oncology Study Update

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium

Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

Price target decreased by 8.9% to US$5.83

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

High number of new and inexperienced directors

Lead Independent Director recently bought US$54k worth of stock

Medicenna extends period to exercise certain warrants

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Price target decreased to US$7.00

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics stock slides on launch of units offering

No longer forecast to breakeven

Price target decreased to US$8.40

Price target increased to US$10.50

High number of new and inexperienced directors

Forecast to breakeven in 2025

Price target decreased to US$9.20

High number of new and inexperienced directors

High number of new and inexperienced directors

Founder recently bought US$85k worth of stock

New 90-day low: US$3.68

New 90-day high: US$5.97

Gewinn- und Umsatzwachstumsprognosen